PT892794E - Prodrogas de n-hidroximetil-talidomida aciladas de efeito imunomodulador - Google Patents

Prodrogas de n-hidroximetil-talidomida aciladas de efeito imunomodulador

Info

Publication number
PT892794E
PT892794E PT97916380T PT97916380T PT892794E PT 892794 E PT892794 E PT 892794E PT 97916380 T PT97916380 T PT 97916380T PT 97916380 T PT97916380 T PT 97916380T PT 892794 E PT892794 E PT 892794E
Authority
PT
Portugal
Prior art keywords
thalidomide
acids
produts
hydroxymethyl
immunomodulatory effect
Prior art date
Application number
PT97916380T
Other languages
English (en)
Portuguese (pt)
Inventor
Johannes Schneider
Stephan Wnendt
Kai Zwingenberger
Werner Winter
Kurt Eger
Michaela Akermann
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of PT892794E publication Critical patent/PT892794E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
PT97916380T 1996-04-09 1997-03-22 Prodrogas de n-hidroximetil-talidomida aciladas de efeito imunomodulador PT892794E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19613976A DE19613976C1 (de) 1996-04-09 1996-04-09 Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Publications (1)

Publication Number Publication Date
PT892794E true PT892794E (pt) 2002-07-31

Family

ID=7790778

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97916380T PT892794E (pt) 1996-04-09 1997-03-22 Prodrogas de n-hidroximetil-talidomida aciladas de efeito imunomodulador

Country Status (12)

Country Link
US (1) US6417197B1 (enExample)
EP (1) EP0892794B1 (enExample)
JP (1) JP2000508298A (enExample)
CN (1) CN1102931C (enExample)
AT (1) ATE212989T1 (enExample)
AU (1) AU707144B2 (enExample)
DE (2) DE19613976C1 (enExample)
DK (1) DK0892794T3 (enExample)
ES (1) ES2171923T3 (enExample)
HU (1) HUP9902181A3 (enExample)
PT (1) PT892794E (enExample)
WO (1) WO1997037988A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
WO1997045117A1 (en) * 1996-05-29 1997-12-04 Prototek, Inc. Prodrugs of thalidomide and methods for using same as modulators of t-cell function
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE19743968C2 (de) * 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
CZ299808B6 (cs) * 1997-11-18 2008-12-03 Celgene Corporation Substituované 2-(2,6-dioxo-3-fluoropiperidin-3-yl)izoindoliny a jejich použití za úcelem snížení hladin TNFalfa
WO2001041755A2 (en) * 1999-12-02 2001-06-14 The Regents Of The University Of Michigan Topical compositions comprising thalidomide for the treatment of inflammatory diseases
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
CN100488959C (zh) * 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
WO2005016326A2 (en) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CN100398534C (zh) * 2003-09-15 2008-07-02 天津和美生物技术有限公司 合成酞胺哌啶酮及其衍生物的方法
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US7973057B2 (en) 2003-09-17 2011-07-05 The United States Of America As Represented By The Department Of Health And Human Services Thalidomide analogs
KR20060118472A (ko) * 2003-10-16 2006-11-23 카이론 코포레이션 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
WO2007120669A1 (en) 2006-04-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
PT2358697E (pt) 2008-10-29 2016-02-03 Celgene Corp Compostos de isoindolina para utilização no tratamento do cancro
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
SG11201805779TA (en) * 2016-01-08 2018-08-30 Celgene Corp Antiproliferative compounds, and their pharmaceutical compositions and uses
WO2019036839A1 (zh) * 2017-08-21 2019-02-28 诺瑞特国际药业股份有限公司 泊马度胺衍生物及其制备方法
CN111499610A (zh) * 2019-01-31 2020-08-07 南京诺瑞特医药科技有限公司 泊马度胺前体药物盐的多晶型物
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
CA2104776C (en) * 1991-04-17 2003-12-09 Kurt Eger Thalidomide derivatives, method of manufacture and use thereof in medicaments
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Also Published As

Publication number Publication date
US6417197B1 (en) 2002-07-09
HUP9902181A3 (en) 2002-11-28
AU2505297A (en) 1997-10-29
ATE212989T1 (de) 2002-02-15
DK0892794T3 (da) 2002-04-15
EP0892794B1 (de) 2002-02-06
JP2000508298A (ja) 2000-07-04
HUP9902181A2 (hu) 2000-04-28
EP0892794A1 (de) 1999-01-27
WO1997037988A1 (de) 1997-10-16
CN1102931C (zh) 2003-03-12
HK1017350A1 (en) 1999-11-19
CN1215397A (zh) 1999-04-28
AU707144B2 (en) 1999-07-01
DE59706313D1 (de) 2002-03-21
DE19613976C1 (de) 1997-11-20
ES2171923T3 (es) 2002-09-16

Similar Documents

Publication Publication Date Title
PT892794E (pt) Prodrogas de n-hidroximetil-talidomida aciladas de efeito imunomodulador
BG93979A (bg) Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им
NO159017C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,2,3,4-tetrahydroisokinolin-3-karboksylsyre-derivater.
ATE222230T1 (de) Substituierte 4-biarylbutyr-oder 5- biarylpentasäuren und derivate als matrix metalloprotease inhibitoren
ATE147272T1 (de) Pharmazeutische zubereitungsformen
ATE52498T1 (de) Amidderivate.
FI915282A0 (fi) Mono-n-substituerade 1,4,7,10-tetra -azacyklododekanderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska aemnen.
DE69209395D1 (de) Therapeutische Amide
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
EA200100983A1 (ru) Производные 13-метилэритромицина
BG106343A (bg) Амиди на карбоксилни киселини, лекарствени средства които ги съдържат, тяхното приложение и получаване
EA200401053A1 (ru) Оксо-азабициклические соединения
IT1251166B (it) Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
NO152047C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksom 5-(paradeuterofenyl)-5-fenylhydantoin
BG60101B2 (bg) Метод за получаване на 4-флуор-2-(((4-метокси-2- пиридинил)метил)тионил)-1н-бензимидазол
FR2707089B1 (fr) Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FI953566A0 (fi) Tahdospironia tai sen analogeja sisältäviä koostumuksia
IL95762A0 (en) Benzanilides,their preparation and pharmaceutical compositions containing the same
ATE92315T1 (de) Aminosaeurederivate enthaltende antikonvulsive zusammensetzungen und verwendung dieser aminosaeurederivate.
AR002264A1 (es) 6-[triazolil[3(trifluormetil)fenil]metil]-2-quinolinonas y quinolintionas, un procedimiento para su preparacion, una composicion que las comprende, unprocedimiento para su preparacion, el uso de las mismas para la preparacion de un medicamento y un intermediario.
ES2170758T3 (es) Antibioticos novedosos de cefalosporina y procedimientos para la preparacion de los mismos.
CA2251060A1 (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
ES8703441A1 (es) Un procedimiento para la preparacion de agentes anti-hiperglicemicos de lactona.
ATE46347T1 (de) Immunostimulierende peptide.
FR2455598A1 (fr) Nouveaux derives 5- (2- ((2,3-dihydro-1,4-benzodioxanne-2-ylmethyl)- amino)-1- hydroxyethyl)-2-hydroxybenzoiques, utiles notamment comme agents bloquants des recepteurs adrenergiques a et b, et leur procede de preparation